Back to Atlas
CTransientStandard research/education caution
CMP-0434
Approved
Raloxifene
Endocrine / SERM
Osteoporosis and breast-cancer-risk reduction positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SERM
- Primary mechanism
- Estrogen receptor modulation; bone agonist/breast antagonist profile
- Primary market use
- Bone health / oncology risk reduction
Pharmacology
- Molecular weight (Da)
- 473.6 base; 510.05 HCl
- Oral bioavailability
- ~2% absolute
- Half-life
- ~27-32 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved
- Clinical status
- Approved
- Value-for-money score
- 6 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Good approved SERM but benefits depend on continued therapy